Experience with solid organ transplantation in patients with previous immunotherapy treatment is still limited but this is changing: The survey-based view of the global transplant society

T. Ivanics*, M. paw Claasen, D. Al-Adra, G. Sapisochin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Downloads (Pure)

Abstract

Background: The use of immunotherapy for cancer is increasing and is expected to continue growing. The outcomes after solid organ transplantation(SOT) in patients who received immunotherapy before SOT remain unclear. We evaluated the global transplant surgery community's attitude towards and experience with patients who received immunotherapy for malignancy before SOT. Methods: An online-based survey was sent to North American transplant program directors in December-2020 and members of the International Liver Transplant Society in November-2021 evaluating experiences with and attitudes towards SOT in recipients with previous immunotherapy for cancer. Results: A total of 119 respondents completed the survey(119/175;completion rate:68%), representing centers from North America, South America, Europe, Asia, and Australia. Seventy-one(62%) respondents would consider SOT in patients with a previous history of immunotherapy for cancer, whereas thirty-nine(34%) were aware of such immunotherapy-treated recipients being transplanted, with an increasing trend over the last few years(2016[n = 1]-2020[n = 14]). Institutional clinical management policies in this setting were lacking in most centers(n = 85[75%]). Conclusions: The international transplant community is receptive to transplanting transplant candidates previously treated with immunotherapy for cancer, although experience is still limited. In this context, more centers have started to offer SOT to patients with a history of immunotherapy for cancer in recent years. However, support from clear and robust institutional policies in this endeavor is scant. Therefore, there is a high need for consensus guidelines to inform future clinical management, especially as immunotherapy for cancer is likely to continue to increase in the coming years.

Original languageEnglish
Article number101637
JournalTransplant Immunology
Volume73
DOIs
Publication statusPublished - Aug 2022

Bibliographical note

Funding Information:
The authors would like to acknowledge the AST LICOP Education Subcommittee and ILTS for their assistance in distributing the survey.

Funding Information:
Gonzalo Sapisochin disclosed consultations for Astra-Zeneca, Roche, Novartis, and Integra. Gonzalo Sapisochin received financial compensation for talks with Roche, Astra-Zeneca, Chiesi, and Integra. Gonzalo Sapisochin has received a grant from Roche. None of the authors have any conflicts of interest to declare.

Publisher Copyright:
© 2022

Fingerprint

Dive into the research topics of 'Experience with solid organ transplantation in patients with previous immunotherapy treatment is still limited but this is changing: The survey-based view of the global transplant society'. Together they form a unique fingerprint.

Cite this